Peter Wang

Dr. Peter Wang

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2022 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
JLJinxin Liu
Jinxin Liu
TCTing Chen
Ting Chen
SLShizhe Li
Shizhe Li
WLWenjun Liu
Wenjun Liu
PWPeter Wang
Peter Wang
GSGuanning Shang
Guanning Shang

21 September 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
ZSZhengwei Song
Zhengwei Song
XWXiaoguang Wang
Xiaoguang Wang
FCFei Chen
Fei Chen
QCQiuli Chen
Qiuli Chen
WLWenjun Liu
Wenjun Liu
PWPeter Wang
Peter Wang
Pancreatic cancer is the fourth leading cause of cancer death in the United States. The main methods of treating pancreatic cancer are surgery and chemotherapy, but the treatment efficacy is low with a poor prognosis. Immunotherapy represented by PD-1/PD-L1 has brought a milestone progress in the treatment of pancreatic cancer. However, the unique tumor microenvironment of pancreatic cancer presents challenges for immunotherapy. In addition, m6A is a common RNA modification and a potential molecular target in tumor therapy. The expression pattern of m6A in pancreatic cancer is still unclear. LncRNAs also play an essential role in pancreatic cancer development and treatment. In this study, we found that some m6A regulators were significantly elevated in pancreatic cancer and associated with the expression of PD-1/PD-L1. Moreover, we observed that METTL3 can increase the expression of PD-L1. Notably, METTL3 positively regulates the expression of lncRNA MALAT1 in pancreatic cancer cells. Strikingly, lncRNA MALAT1 increased the expression of PD-L1 in pancreatic cancer cells. This finding indicated that METTL3 regulated the expression of PD-L1 possibly via targeting lncRNA MALAT1 in pancreatic cancer cells. Lastly, MALAT1 governed the viability of pancreatic cancer cells. Taken together, lncRNA MALAT1 is involved in METTL3-mediated promotion of PD-L1 expression in pancreatic cancer.

9 November 2022 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
WWWeijia Wang
Weijia Wang
WLWenjun Liu
Wenjun Liu
QCQiuli Chen
Qiuli Chen
YYYong Yuan
Yong Yuan
PWPeter Wang
Peter Wang

9 June 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
CZChenxiao Zheng
Chenxiao Zheng
JCJiayi Chen
Jiayi Chen
YWYurui Wu
Yurui Wu
XWXiaochao Wang
Xiaochao Wang
YLYongan Lin
Yongan Lin
PWPeter Wang
Peter Wang
Osteoarthritis is non-inflammatory degenerative joint arthritis, which exacerbates disability in elder persons. The molecular mechanisms of osteoarthritis are elusive. Ubiquitination, one type of post-translational modifications, has been demonstrated to accelerate or ameliorate the development and progression of osteoarthritis via targeting specific proteins for ubiquitination and determining protein stability and localization. Ubiquitination process can be reversed by a class of deubiquitinases via deubiquitination. In this review, we summarize the current knowledge regarding the multifaceted role of E3 ubiquitin ligases in the pathogenesis of osteoarthritis. We also describe the molecular insight of deubiquitinases into osteoarthritis processes. Moreover, we highlight the multiple compounds that target E3 ubiquitin ligases or deubiquitinases to influence osteoarthritis progression. We discuss the challenge and future perspectives via modulation of E3 ubiquitin ligases and deubiquitinases expression for enhancement of the therapeutic efficacy in osteoarthritis patients. We conclude that modulating ubiquitination and deubiquitination could alleviate the osteoarthritis pathogenesis to achieve the better treatment outcomes in osteoarthritis patients.

8 August 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
ZXZhiyuan Xu
Zhiyuan Xu
QCQiuli Chen
Qiuli Chen
LSLilu Shu
Lilu Shu
CZChunye Zhang
Chunye Zhang
WLWenjun Liu
Wenjun Liu
PWPeter Wang
Peter Wang
Gastric cancer is the fourth most frequent cancer and has a high death rate. Immunotherapy represented by PD-1 has brought hope for the treatment of advanced gastric cancer. Methylation of the m6A genes is linked to the onset and progression of numerous cancers, but there are few studies on gastric cancer. The main purpose of this study aims to analyze the relationship between m6A RNA methylation regulators, PD-L1, prognosis and tumor immune microenvironment (TIME) in gastric cancer. The Cancer Genome Atlas (TCGA) and Genotype Tissue Expression (GTEx) databases were used to acquire transcriptomic data and clinical information from gastric cancer patients. The changes in m6A regulator expression levels in gastric cancer tissues and normal tissues were studied. Consensus clustering analysis was used to separate gastric cancer samples into two categories. We employed Least Absolute Shrinkage, Selection Operator (LASSO) Cox regression analysis, Gene Set Enrichment Analysis (GSEA), and cBioPortal to analyze the m6A regulators, PD-L1 and TIME in gastric cancer. In gastric cancer tissues, the majority of m6A regulatory factors are considerably overexpressed. Two gastric cancer subgroups (Cluster1/2) based on consensus clustering of 21 m6A regulators. PD-L1 and PD-1 expression levels were significantly higher in gastric cancer tissues, and they were significantly linked with METTL3, WTAP, HNRNPD, ZC3H7B, METTL14, FTO, PCIF1, HNRNPC, YTHDF1 and YTDHF2. Cluster1 showed a large increase in resting memory CD4+ T cells, regulatory T cells, naïve B cells, active NK cells, and resting Mast cells. Cluster1 and Cluster2 were shown to be involved in numerous critical signaling pathways, including base excision repair, cell cycle, nucleotide excision repair, RNA degradation, and spliceosome pathways. Gastric cancer RiskScores based on prognostic factors have been found as independent prognostic indicators. The amount of tumor-infiltrating immune cells is dynamically affected by changes in the copy number of m6A methylation regulators associated with TIME.

6 September 2022 in Seminars in Cell & Developmental Biology
Verified
Journal Article
Closed access
TCTing Chen
Ting Chen
JLJinxin Liu
Jinxin Liu
SLShizhe Li
Shizhe Li
PWPeter Wang
Peter Wang
GSGuanning Shang
Guanning Shang